The antipsychotic effect of clozapine, synthesized in 1959, was demonstrated in 1966. After the occurrence of an epidemic of agranulocytosis in 1976, clozapine was withdrawn from the market only to be authorized in 1991 in France. In Tunisia, clozapine began to be marketed in the late 1990s. However, its prescription remains limited despite it remaining the reference molecule for the treatment of resistant schizophrenia.Rigorous therapeutic monitoring makes it possible to monitor the appearance of adverse effects. The objective of the study is to evaluate the clinical, biological and pharmacological follow-up methods of patients treated with clozapine in relation to international recommendations and to study the correlation between the plasma levels of clozapine and clinical psychotic signs.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.